News
(2)April 2026
Dyne Therapeutics DYN Annual Report Details Genetic Muscle Disease Therapies Pipeline
Since the actual text of the ARS (Annual Report to Shareholders) for Dyne Therapeutics wasn't included in your message, I'll create a clear, educational breakdown of what this document is and what you would typically find inside it, based on what an ARS contains and public knowledge about Dyne. # �
DYN Proposes Doubling Authorized Shares at Annual Meeting
# 🧾 What This Document Is This is Dyne Therapeutics' **Definitive Proxy Statement (DEF 14A)**. Think of it as the official agenda and background packet for the company's upcoming annual shareholder meeting. It’s sent so shareholders can vote on key company decisions. 👉 **Why it matters:** Your vo
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.